1. Home
  2. MIRM vs AVAL Comparison

MIRM vs AVAL Comparison

Compare MIRM & AVAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • AVAL
  • Stock Information
  • Founded
  • MIRM 2018
  • AVAL 1994
  • Country
  • MIRM United States
  • AVAL Colombia
  • Employees
  • MIRM N/A
  • AVAL N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • AVAL Commercial Banks
  • Sector
  • MIRM Health Care
  • AVAL Finance
  • Exchange
  • MIRM Nasdaq
  • AVAL Nasdaq
  • Market Cap
  • MIRM 2.1B
  • AVAL 2.4B
  • IPO Year
  • MIRM 2019
  • AVAL N/A
  • Fundamental
  • Price
  • MIRM $46.95
  • AVAL $2.25
  • Analyst Decision
  • MIRM Strong Buy
  • AVAL
  • Analyst Count
  • MIRM 11
  • AVAL 0
  • Target Price
  • MIRM $57.00
  • AVAL N/A
  • AVG Volume (30 Days)
  • MIRM 450.2K
  • AVAL 51.2K
  • Earning Date
  • MIRM 02-26-2025
  • AVAL 03-03-2025
  • Dividend Yield
  • MIRM N/A
  • AVAL 5.07%
  • EPS Growth
  • MIRM N/A
  • AVAL 150.80
  • EPS
  • MIRM N/A
  • AVAL 0.01
  • Revenue
  • MIRM $307,028,000.00
  • AVAL $2,745,537,342.00
  • Revenue This Year
  • MIRM $82.14
  • AVAL N/A
  • Revenue Next Year
  • MIRM $26.18
  • AVAL $15.37
  • P/E Ratio
  • MIRM N/A
  • AVAL $13.35
  • Revenue Growth
  • MIRM 112.14
  • AVAL N/A
  • 52 Week Low
  • MIRM $23.14
  • AVAL $1.94
  • 52 Week High
  • MIRM $48.89
  • AVAL $2.71
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 65.98
  • AVAL 66.37
  • Support Level
  • MIRM $40.55
  • AVAL $2.21
  • Resistance Level
  • MIRM $47.25
  • AVAL $2.18
  • Average True Range (ATR)
  • MIRM 1.49
  • AVAL 0.05
  • MACD
  • MIRM 0.56
  • AVAL 0.02
  • Stochastic Oscillator
  • MIRM 95.52
  • AVAL 90.74

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About AVAL Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

Grupo Aval Acciones y Valores SA is a Colombian financial services company. Its local operations consist of commercial banking (Banco de Bogota, Banco de Occidente, Banco Popular, and Banco AV Villas), pension fund management (Porvenir), and merchant banking (Corficolombiana). Outside Colombia, the company offers (via BAC Credomatic operations) consumer and credit card banking businesses in Central American countries (Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama) and Mexico. BAC Credomatic has key alliances with major credit card networks, such as Visa, MasterCard, American Express, and Diners Club.

Share on Social Networks: